Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

Multiple presentations at ASM Microbe 2017 confirm VT-1598’s broad spectrum of activity and highlight its potential against multi-drug resistant fungal pathogens

Viamet Pharmaceuticals, Inc. today announced the presentation of multiple studies supporting VT-1598, a clinical-stage compound for the treatment of life-threatening invasive fungal infections, at the American Society for Microbiology’s ASM Microbe 2017 conference in New Orleans, Louisiana. Data presented at the conference demonstrate that VT-1598 is highly active against pathogenic molds, yeasts and endemic fungi, including Candida auris (C. auris) and other multi-drug resistant fungal pathogens.